United Bid to Liberalize Use of Psilocybin Strengthens

  • Leading UK scientists, policy group call for rescheduling of psilocybin amid looming mental health crisis
  • Sent to the Home Office with statements of support from leading scientists, paper urges for psilocybin use on a research-only model
  • Cybin Corp. to capitalize on international expansion of psilocybin use as a company active in both research, nonclinical spaces

The United Kingdom (“UK”) is joining other countries, including Canada, in a push to facilitate the wider use of psilocybin, a naturally occurring compound found in mushrooms. Focusing on psychedelic and nutraceutical products, Cybin Corp. is poised to leverage the growing global momentum the compound is gaining.

Recent clinical studies suggest that psilocybin may be a safe and effective drug for patients with certain treatment-resistant psychiatric illnesses (https://ibn.fm/dsIEN). Despite that, researchers claim their work is hindered by strict controls on the compound. The Adam Smith Institute and the Conservative Drug Policy Reform Group recently published a joint paper that calls for a review of the Schedule 1 status of psilocybin (https://ibn.fm/TMGvg). That status inhibits research efforts despite the compound’s potential to contribute to the treatment of several highly prevalent mental health disorders.

The paper is co-published and authored by leading researchers from prominent academic institutions including King’s College London and the University of Manchester. The authors of the paper propose the re-classification of psilocybin to Schedule 2 of the Misuse of Drugs Regulations 2001 on a research-only basis. Doing so would reduce current barriers to research, enabling the enormously needed exploration of novel mental health treatments by the UK’s scientists.

Psilocybin was used in the psychiatric treatment for resistant forms of depression, anxiety, and addictions before 1970. The drug was banned that year as a result of the U.S.-led war on drugs. Decades later, psilocybin is experiencing a slow but steady revival of research interest. Leading academic institutions are advocating for easier use of the compound in the academic and clinical setting (https://ibn.fm/ud5zY).

Consequently, countries around the world are becoming increasingly accepting of psilocybin use in a controlled setting. Recently, Canada’s health department has allowed its use for palliative care of terminally ill patients (https://ibn.fm/ZkBgz).

Big Pharma has scaled back investment in mental health research, failing to offer more effective treatments for health problems plaguing hundreds of millions of people worldwide (https://ibn.fm/jqSV4). Fortunately, innovative companies are stepping up to fill the growing need for novel psychiatric drugs.

Cybin already holds a unique strength in the psychedelics space. The company is responsible for some of the first published research on microdosing; i.e, the action or practice of taking or administering very small amounts of a drug to test or benefit from its physiological action while minimizing its potentially undesirable side effects. Microdosing sub-hallucinogenic amounts of psychedelic drugs including psilocybin has several potentially positive indications. As such, Cybin is ideally positioned to leverage the growing acceptance of psilocybin in mainstream space.

Cybin is active in two critical sectors: nutraceutical and pharmaceutical. In the nutraceutical market, the company’s wholly owned subsidiary Nature’s Journey focuses on adaptogenic mushroom products. Meanwhile, Cybin is an innovator in the stagnant pharmaceutical market, where it aims to become the first life science company to bring psilocybin medicine targeting major depressive disorder to market (https://ibn.fm/4a2Xw).

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.


Select A Month

PsychedelicNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 415.949.5050